Lorglumide is primarily used in research settings to study the role of cholecystokinin (CCK) receptors in the body. It acts as a selective antagonist for CCK-A receptors, making it a valuable tool in understanding gastrointestinal and pancreatic functions. Researchers utilize it to explore its effects on appetite regulation, digestion, and bile secretion. Additionally, lorglumide has been investigated for its potential role in modulating anxiety and pain pathways, as CCK receptors are also involved in the central nervous system. Its application extends to preclinical studies aimed at developing therapeutic agents for conditions like obesity, pancreatitis, and certain psychiatric disorders.